丹参酮ⅡA磺酸钠联合依达拉奉治疗急性脑梗死的临床效果研究

Clinical effects of sodium tanshinone ⅡA sulfonate combined with edaravone on patients with acute cerebral infarction

目的探讨丹参酮ⅡA磺酸钠联合依达拉奉治疗急性脑梗死的疗效。方法回顾性分析2015年2月至2016年9月100例急性脑梗死的患者,随机分为研究组和对照组,每组50例,两组患者均给予抗血小板聚集、营养脑神经、维持水电解质平衡、改善脑循环联合依达拉奉等基础治疗,研究组加用丹参酮ⅡA磺酸钠。分析两组治疗前NIHSS评分、血脂及血清CRP;两组急性脑梗死治疗疗效;两组治疗前和治疗后血清炎性因子水平。结果研究组和对照组NIHSS评分、血脂及血清CRP的水平比较差异未见统计学意义(P>0.05)。研究组治疗有效率为80%,高与对照组的64%,差异有统计学意义(P<0.05)。研究组和对照组治疗前血清炎性因子比较,差异未见统计学意义(P>0.05);研究组和对照组治疗后血清炎性因子比较,差异有统计学意义(P<0.05)。结论丹参酮ⅡA磺酸钠联合依达拉奉可以提高急性脑梗死的治疗疗效,减轻急性期血清中炎症水平。

Objective To investigate the effects of sodium tanshinone II A sulfonate combined with edaravone on patients with acute cerebral infarction. Methods The clinical .data of 100 patients with acute cerebral infarction admitted from February 2015 to September 2016 were retrospectively ana- lyzed. They were randomly divided into the study group and the control group, with 50 cases in each group. The patients in the two groups were treated with basic treatment, including anti-platelet aggrega- tion, nutritional brain nerve, maintenance of water and electrolyte balance, improvement of cerebral cir- culation combined with edaravone, and the patients in the study group were added with sodium tanshi- none II A sulfonate. The NIHSS scores, blood lipids and the serum CRP levels, serum inflammatory fac- tors were compared between the two groups before and after the treatment, and the therapeutic effects of the two groups were compared. Results There were no significant difference in NIHSS scores, blood lipid and serum CRP between the two groups （ P 〉 0.05 ）, and the total effective rate in the study group was 80% , which was higher than that （64%） in the control group, the difference was significant （P 〈 0. 05）. Before treatment, there was no significant difference in serum inflammatory factors between the study group and the control group （P 〉 0.05 ）. After treatment, the difference in serum inflammatory fac- tors between the study group and the control group was significant （ P 〈 0. 05 ）. Conclusions Sodium tanshinone ⅡA sulfonate combined with edaravone can improve the therapeutic effects of the patients with acute cerebral infarction, and reduce the serum inflammatory level in acute phase.